Opioid Dependence and Its Treatment: Agonists, Partial Agonists and Antagonists
The naloxone chapter is about the crash — the blue, apnoeic patient who needs their receptors emptied in seconds. This chapter is about everything that happens between the crashes: the slow rewiring of a brain around a drug, the misery of withdrawal, and the quietly brilliant pharmacology that treats it. The remarkable thing is that the three medicines that pull people out of opioid use disorder are the three textbook categories of receptor drug — a full agonist, a partial agonist, and an antagonist — each doing its job at the very same mu receptor. Get the pharmacology, and the whole treatment logic falls into place.
A 29-year-old man arrives at the clinic sixteen hours after his last dose of heroin. He is not dying — his airway is fine, his pupils are wide, not pinpoint — but he is in agony. He yawns compulsively, his nose streams, tears run down a face he can't keep still; gooseflesh stands up along his arms, his gut cramps and turns to diarrhoea, and every muscle aches as if he has influenza. He is restless, sweating, pleading. This is the exact photographic negative of the overdose patient in the naloxone chapter: where overdose brings pinpoint pupils, no breathing and coma, withdrawal brings blown pupils, streaming secretions and a body that will not be still. It rarely kills an adult — but it is severe enough to drive people straight back to the drug. Treating it well is how you keep him alive long enough to recover.
How a brain becomes dependent
Dependence is not weakness — it is neuroadaptation, and it obeys pharmacology. Every opioid high works through the mu (μ) receptor — the same receptor covered in the Central Nervous System section, coupled to inhibitory G-proteins that quiet neurons and, in the reward pathway, release dopamine. Flood that receptor day after day and the neuron fights back. It down-regulates its response and dials up the opposing systems (notably the noradrenergic neurons of the locus coeruleus) to restore a normal baseline while the drug is present. This is tolerance: the same dose now does less, so the dose climbs. But a neuron re-tuned to function normally only in the presence of the opioid has a hidden cost — remove the drug and that ramped-up opposing machinery is suddenly unopposed. The suppressed noradrenergic system fires unchecked. That rebound is the withdrawal syndrome. Tolerance and physical dependence are two faces of the same adaptation, exactly as the Principles of Pharmacology chapter frames it.
The withdrawal syndrome: the toxidrome in reverse
The cleanest way to remember opioid withdrawal is to take the overdose toxidrome and invert every sign. Overdose gives pinpoint pupils; withdrawal gives dilated (mydriatic) pupils. Overdose depresses secretions and breathing; withdrawal opens the taps — yawning, lacrimation (watering eyes), rhinorrhoea (running nose), sweating. Overdose brings constipation and stillness; withdrawal brings abdominal cramps, nausea, vomiting and diarrhoea, with piloerection ("cold turkey"), muscle and joint aches, restlessness and agitation. Note what is absent: no respiratory depression, no coma. Unlike alcohol or benzodiazepine withdrawal — which can seize and kill — uncomplicated opioid withdrawal in an otherwise healthy adult is intensely unpleasant but rarely fatal. The danger is indirect: dehydration in the frail, and above all relapse, because the fastest way to end the misery is another dose — into now-reduced tolerance.
Picture a heavy truck that has been climbing a hill with the engine at full throttle to hold a steady speed. The opioid is a strong tailwind pushing from behind; over weeks the driver keeps flooring the accelerator (the brain's opposing systems ramping up) just to stay at the limit. Cut the tailwind suddenly — stop the drug — and nothing counteracts that wide-open throttle. The truck lurches forward, over-revving and shuddering. Withdrawal is that lurch: the body's compensatory systems, built up to oppose the opioid, are left roaring against nothing. The treatments each work by easing the throttle back down gradually rather than yanking the tailwind away all at once.
Methadone — the full agonist that stabilises
Replace the chaotic drug with a smooth, long-acting one at the same receptor. Methadone is a full mu agonist — pharmacologically it does what heroin does — but two properties transform it into a treatment rather than a repeat of the problem. First, taken by mouth once daily, it has a long half-life, so blood levels stay flat instead of spiking and crashing. That flatness abolishes the reward "rush" of an injected drug and abolishes the trough of withdrawal; the patient is neither high nor sick, just stable, and can rebuild a life. Second, given under supervision it removes the injecting, the illicit supply and the overdose roulette. The cost is that a full agonist has no ceiling: methadone itself can cause fatal respiratory depression, and the danger is highest during induction, before tolerance to the new drug is established. It also prolongs the QT interval and interacts with many drugs. Methadone is powerful and effective — and, uniquely among the three, it can kill by the same mechanism as the drug it replaces.
Buprenorphine — the partial agonist with a ceiling
Buprenorphine is the pharmacology lesson made concrete. It is a high-affinity partial mu agonist: it binds the receptor very tightly but only ever produces a submaximal effect no matter how much you give. That submaximal ceiling is the whole point — it is enough opioid effect to suppress withdrawal and craving, but respiratory depression plateaus rather than climbing indefinitely, so buprenorphine is far safer in overdose than methadone. Its high affinity has a second consequence: it out-competes and displaces full agonists like heroin from the receptor. If you give it to someone comfortably full of heroin, it knocks the stronger agonist off and replaces it with its own weaker signal — and the sudden drop in mu activation precipitates withdrawal within minutes. This is the induction-timing trap: buprenorphine must be started only once the patient is already in early withdrawal, never while a full agonist still occupies the receptor. It is usually dispensed combined with naloxone (as a sublingual tablet/film); taken correctly the naloxone is barely absorbed, but if the combination is dissolved and injected the naloxone becomes active and blocks the high — a clever deterrent to misuse.
"Precipitated withdrawal" is where the naloxone chapter and this one meet. Naloxone precipitates it deliberately and instantly by fully emptying the receptor in an overdose. Buprenorphine precipitates it accidentally when started too early, because a partial agonist replacing a full agonist is a net drop in mu signalling. Same phenomenon — a sudden fall in receptor activation — reached from opposite directions. Understand affinity versus efficacy (a drug can bind hard yet do little), and both stop being surprising: buprenorphine wins the seat but sits more quietly than the drug it evicted.
Naltrexone — the antagonist that blockades
Not a substitute at all — a lock on the door. Naltrexone takes the opposite strategy: it is a pure mu antagonist. It occupies the receptor, produces no opioid effect itself, and — because it sits there — blocks any opioid the person subsequently takes. Take heroin on top of naltrexone and you feel nothing; the reward is gone, and so, over time, is the point of using. This makes it a relapse-prevention (maintenance) tool for the already-detoxified patient, not a treatment for withdrawal. It is the same molecule as naltrexone's short-acting cousin naloxone from the overdose chapter, but built for months not minutes, and available as a long-acting monthly depot injection that removes the daily decision to stay abstinent. The critical rule mirrors buprenorphine's from the other side: the patient must be fully opioid-free first (typically 7–10 days, longer for methadone). Give an antagonist to someone still physically dependent and it strips the receptors bare in one move, precipitating severe, abrupt withdrawal. And a sober warning: after a period on naltrexone (or any abstinence) tolerance is lost, so a relapse at the old dose can be fatal — a direct handoff to the naloxone/overdose chapter and to take-home naloxone.
Methadone — full mu agonist, oral, long half-life, supervised: stabilises but no ceiling (fatal respiratory depression, QT prolongation, drug interactions; danger peaks at induction). Buprenorphine (often with naloxone, e.g. Suboxone) — high-affinity partial mu agonist, sublingual: safer ceiling on respiratory depression, but precipitates withdrawal if started too early. Naltrexone — mu antagonist, oral or monthly depot injection: blocks the effect of opioids for relapse prevention, but the patient must be opioid-free first and loses tolerance while on it. One receptor, three textbook drug classes — full agonist, partial agonist, antagonist — which is why opioid use disorder is the cleanest clinical illustration of receptor pharmacology in all of medicine.
- Dependence is neuroadaptation at the mu receptor: tolerance and physical dependence are two faces of the same change.
- Withdrawal is the opioid toxidrome in reverse — dilated pupils, yawning, lacrimation, rhinorrhoea, piloerection, cramps, myalgia, agitation.
- Unlike alcohol/benzodiazepine withdrawal, opioid withdrawal is rarely fatal — but severe enough to drive relapse.
- Methadone = full agonist: stabilises with steady levels, but no ceiling — can cause fatal respiratory depression and prolongs QT.
- Buprenorphine = high-affinity partial agonist: ceiling on respiratory depression (safer), but precipitates withdrawal if started too soon.
- Naltrexone = antagonist: blocks opioids for relapse prevention, but only after full detox — and tolerance is lost while on it.
Managing the withdrawal itself
Sometimes the goal is not maintenance but getting a patient comfortably through withdrawal — and here the pharmacology loops back to the Autonomic section. Much of the withdrawal storm is a runaway noradrenergic surge from the locus coeruleus. So the classic symptomatic agents are alpha-2 adrenergic agonists: clonidine, and the more selective lofexidine (licensed specifically for opioid withdrawal). By stimulating the presynaptic alpha-2 autoreceptor, they dial down central noradrenaline release and blunt the autonomic features — sweating, cramping, tachycardia, agitation — without touching the mu receptor at all (watch for hypotension and sedation). Around that core you add simple symptomatic cover: antiemetics for nausea and vomiting, antidiarrhoeals (loperamide, a peripherally-acting opioid), NSAIDs or other analgesics for the muscle and joint pain, and something for insomnia. None of this is a cure for the disorder — it is bridging comfort. Long-term outcomes are far better with maintenance agonist therapy (methadone or buprenorphine) than with detox-and-abstinence alone, which carries a high relapse rate.
Harm reduction: keeping people alive to recover
Pharmacology alone doesn't save the person who relapses on a Friday night with no one watching — public-health measures do. Take-home naloxone puts the overdose antidote (the subject of its own chapter) into the hands of users and their families, so a witnessed overdose can be reversed before the ambulance arrives; the loss of tolerance after any abstinence makes this especially vital. Needle and syringe programmes cut the transmission of HIV and hepatitis C that otherwise ride along with injecting. Supervised consumption services and drug-checking reduce fatal overdose, particularly now that illicit supplies are increasingly contaminated with high-potency synthetic opioids like fentanyl that overwhelm ordinary tolerance. These measures don't treat dependence — they keep people alive and in contact with services long enough for the agonist and antagonist pharmacology above to do its work.
- Symptomatic withdrawal relief centres on alpha-2 agonists (clonidine, lofexidine) that blunt the noradrenergic autonomic storm.
- Add antiemetics, antidiarrhoeals (loperamide), analgesics and sleep aids as bridging comfort — none treats the underlying disorder.
- Maintenance agonist therapy (methadone/buprenorphine) beats detox-and-abstinence alone, which relapses heavily.
- Tolerance falls fast during any abstinence — the returning-to-old-dose relapse is a leading cause of fatal overdose.
- Harm reduction — take-home naloxone, needle programmes, drug-checking — keeps people alive long enough to be treated.
- Starting buprenorphine while a full agonist still occupies the receptor — its high affinity displaces the agonist and precipitates acute withdrawal. Wait for early withdrawal first.
- Giving naltrexone to a patient who is not fully detoxified — an antagonist strips a dependent receptor bare and causes severe precipitated withdrawal.
- Treating opioid withdrawal as life-threatening like alcohol withdrawal, or dismissing it as trivial — it rarely kills directly but is severe and the relapse it drives is what kills.
A man who used heroin around six hours ago, and is not yet in withdrawal, is given his first dose of buprenorphine. Within twenty minutes he becomes acutely unwell — dilated pupils, yawning, sweating, vomiting and severe agitation. What best explains this?
- Opioid dependence is mu-receptor neuroadaptation; stopping the drug unmasks a noradrenergic rebound — withdrawal, the toxidrome in reverse (dilated pupils, yawning, lacrimation, rhinorrhoea, cramps, myalgia), severe but rarely fatal.
- Three medicines = three receptor classes at the mu receptor: methadone (full agonist, stabilises but no ceiling), buprenorphine (partial agonist, safer ceiling but precipitates withdrawal if too early), naltrexone (antagonist, relapse prevention after full detox).
- Symptomatic withdrawal is managed with alpha-2 agonists (clonidine, lofexidine) plus antiemetics, antidiarrhoeals and analgesics — comfort, not cure.
- Harm reduction (take-home naloxone, needle programmes, drug-checking) keeps people alive; tolerance is lost during abstinence, so relapse at the old dose can be fatal.
- Goldfrank's Toxicologic Emergencies — Opioids and opioid withdrawal.
- Rang & Dale's Pharmacology — Opioid analgesics; drug dependence and the mu receptor.
- Katzung Basic & Clinical Pharmacology — Opioid agonists & antagonists; drugs of abuse.
- British National Formulary (BNF) — Opioid dependence: methadone, buprenorphine, naltrexone, lofexidine.
- WHO Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.
- SAMHSA / ASAM National Practice Guideline for the Treatment of Opioid Use Disorder.
